As of 2026-03-23, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -15.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 2,018.92 mil USD. NKTR's TTM EBITDA according to its financial statements is -129.38 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 14.8x | 11.3x |
| Forward P/E multiples | 12.2x - 13.7x | 12.6x |
| Fair Price | (59.70) - (66.81) | (58.30) |
| Upside | -182.7% - -192.5% | -180.7% |
| Date | EV/EBITDA |
| 2026-03-20 | -15.60 |
| 2026-03-19 | -16.16 |
| 2026-03-18 | -15.81 |
| 2026-03-17 | -16.20 |
| 2026-03-16 | -15.60 |
| 2026-03-13 | -15.82 |
| 2026-03-12 | -15.21 |
| 2026-03-11 | -15.84 |
| 2026-03-10 | -15.57 |
| 2026-03-09 | -14.96 |
| 2026-03-06 | -15.28 |
| 2026-03-05 | -15.65 |
| 2026-03-04 | -15.37 |
| 2026-03-03 | -14.74 |
| 2026-03-02 | -14.79 |
| 2026-02-27 | -14.92 |
| 2026-02-26 | -14.27 |
| 2026-02-25 | -15.21 |
| 2026-02-24 | -14.80 |
| 2026-02-23 | -15.90 |
| 2026-02-20 | -15.92 |
| 2026-02-19 | -15.95 |
| 2026-02-18 | -15.81 |
| 2026-02-17 | -15.94 |
| 2026-02-13 | -15.42 |
| 2026-02-12 | -15.35 |
| 2026-02-11 | -14.37 |
| 2026-02-10 | -12.18 |
| 2026-02-09 | -8.19 |
| 2026-02-06 | -8.14 |
| 2026-02-05 | -7.78 |
| 2026-02-04 | -8.31 |
| 2026-02-03 | -8.57 |
| 2026-02-02 | -8.41 |
| 2026-01-30 | -8.25 |
| 2026-01-29 | -7.80 |
| 2026-01-28 | -7.95 |
| 2026-01-27 | -8.39 |
| 2026-01-26 | -8.21 |
| 2026-01-23 | -8.20 |
| 2026-01-22 | -8.08 |
| 2026-01-21 | -8.16 |
| 2026-01-20 | -8.01 |
| 2026-01-16 | -8.32 |
| 2026-01-15 | -7.83 |
| 2026-01-14 | -7.98 |
| 2026-01-13 | -8.09 |
| 2026-01-12 | -8.55 |
| 2026-01-09 | -8.75 |
| 2026-01-08 | -9.11 |